Thyroid hormone enhances the ability of serum to accept cellular cholesterol via the ABCA1 transporter
- 1 September 2011
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 218 (1) , 77-82
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in MicePLOS ONE, 2010
- Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivoJournal of Lipid Research, 2009
- The thyromimetic T-0681 protects from atherosclerosisJournal of Lipid Research, 2009
- Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol effluxJournal of Lipid Research, 2009
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentNature Medicine, 2008
- Characterization and properties of preβ-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-IJournal of Lipid Research, 2008
- The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humansProceedings of the National Academy of Sciences, 2008
- Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic indexProceedings of the National Academy of Sciences, 2007